Revolution Medicines, Inc. Increase (Decrease) in Other Noncurrent Assets
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Other Noncurrent Assets of $12.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-02-25
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $154.00K.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was -$3.79M.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-06-30 was $17.27M, a 318.54% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-03-31 was -$765.00K.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was $12.87M.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was -$1.69M.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was -$870.00K, a 138.72% decline from fiscal 2022.
- Revolution Medicines, Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $2.25M.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 9 month as first filed | Increase (Decrease) in Other Noncurrent Assets 12 month | Increase (Decrease) in Other Noncurrent Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$3.64M derived: sum of 2 quarters · filed 2026-02-25 | $13.64M derived: sum of 3 quarters · filed 2026-02-25 | $12.87M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | -$3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.48M derived: sum of 2 quarters · filed 2025-11-05 | $12.72M 10-Q · filed 2025-11-05 | $10.22M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2025-06-30 | $17.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $16.51M 10-Q · filed 2025-08-06 | $14.02M derived: sum of 3 quarters · filed 2026-02-25 | $10.82M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2025-03-31 | -$765.00K 10-Q · filed 2025-05-07 | -$3.26M derived: sum of 2 quarters · filed 2026-02-25 | -$6.46M derived: sum of 3 quarters · filed 2026-02-25 | -$2.33M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-12-31 | -$2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$5.69M derived: sum of 2 quarters · filed 2026-02-25 | -$1.56M derived: sum of 3 quarters · filed 2026-02-25 | -$1.69M 10-K · filed 2026-02-25 | $5.88M 10-K · filed 2025-02-26 | |
| 2024-09-30 | -$3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $930.00K derived: sum of 2 quarters · filed 2025-11-05 | $805.00K 10-Q · filed 2025-11-05 | $5.88M 10-Q · filed 2024-11-06 | -$8.56M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.00M 10-Q · filed 2025-08-06 | -$5.36M derived: sum of 3 quarters · filed 2026-02-25 | $3.31M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | -$125.00K 10-Q · filed 2025-05-07 | -$9.49M derived: sum of 2 quarters · filed 2026-02-25 | -$817.00K derived: sum of 3 quarters · filed 2026-02-25 | -$905.00K derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | -$9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$692.00K derived: sum of 2 quarters · filed 2026-02-25 | -$780.00K derived: sum of 3 quarters · filed 2026-02-25 | -$870.00K 10-K · filed 2026-02-25 | $1.41M 10-K · filed 2024-02-26 | |
| 2023-09-30 | $8.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $8.59M derived: sum of 2 quarters · filed 2024-11-06 | $8.49M 10-Q · filed 2024-11-06 | $10.55M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$178.00K 10-Q · filed 2024-08-07 | $1.87M derived: sum of 3 quarters · filed 2025-02-26 | $2.03M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | -$90.00K 10-Q · filed 2024-05-08 | $1.96M derived: sum of 2 quarters · filed 2025-02-26 | $2.11M derived: sum of 3 quarters · filed 2025-02-26 | $2.04M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.20M derived: sum of 2 quarters · filed 2025-02-26 | $2.13M derived: sum of 3 quarters · filed 2025-02-26 | $2.25M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $82.00K derived: sum of 2 quarters · filed 2023-11-06 | $196.00K 10-Q · filed 2023-11-06 | $115.00K derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $43.00K 10-Q · filed 2023-08-08 | -$38.00K derived: sum of 3 quarters · filed 2024-02-26 | -$38.00K derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-03-31 | $114.00K 10-Q · filed 2023-05-08 | $33.00K derived: sum of 2 quarters · filed 2024-02-26 | $33.00K derived: sum of 3 quarters · filed 2024-02-26 | $33.00K derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2021-12-31 | -$81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$81.00K derived: sum of 2 quarters · filed 2024-02-26 | -$81.00K derived: sum of 3 quarters · filed 2024-02-26 | -$81.00K 10-K · filed 2024-02-26 | $81.00K 10-K · filed 2022-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | $266.00K derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $266.00K derived: sum of 3 quarters · filed 2023-02-27 | $135.00K derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $266.00K derived: sum of 2 quarters · filed 2023-02-27 | $135.00K derived: sum of 3 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $135.00K derived: sum of 2 quarters · filed 2023-02-27 | -$139.00K 10-K · filed 2023-02-27 | |||
| 2020-09-30 | -$131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$405.00K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | -$274.00K 10-Q · filed 2021-08-11 | |||||
| 2019-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $65.00K 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.19M derived: sum of 2 quarters · filed 2020-11-12 | $1.26M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $65.00K 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | $65.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |